Table 3.

Experimental Brain Metastasis Preventive Activity of Compounds in the 231-BR Model.

Drug:	Dose andSchedule2:	Expt3:	Median4 Number Large Metastases:		%Reduction:	P:	Ref.:
			Vehicle	Drug
Capecitabine	400 D PO	1	6.2	4.8	−23	0.40
		2	2.7	1.7	−37	0.59
		3	3.0	1.9	−37	1.0
Carboplatin	50 W IV	1	6.2	3.6	−42	0.32
		2	3.0	3.0	0	1.0
Doxorubicin	5 W IV	1	6.2	5.4	−13	0.04
Gemcitabine	50 2xW IV	1	2.7	0	−100	0.008
		2	2.0	0	−100	<0.0001
Irinotecan	4×7 IV	1	2.0	1.0	−50	0.090
		2	3.8	1.8	−53	0.010
Paclitaxel	6 W IV	1	8.5	7.4	−13	1.0
		2	3.9	4.8	+23	0.75
		3	6.2	4.0	−35	0.65
Lapatinib5	100 Dx2 PO	P	6.8	3.4	−50	0.0001	(109)
Vorinostat	150 D IP	P	7.7*	2.9*	−62	<0.0001	(110)
Pazopanib5	100 Dx2 PO	P	3.9	1.1	−73	<0.0001	(111)
TPI-287	18 3×4 IV	P	4.3*	1.9*	−55	0.025	(112)

^1.Includes previously published and unpublished results, the latter without references and conducted in the Steeg laboratory.

^2.Dose in mg/kg. D, Daily; Dx2, Twice daily; M-F, Daily- Monday through Friday; W, Weekly; 2xW, Twice weekly; 4×7, Every fourth day for 7 treatments; 4×5–2, Two doses of 5 mg/kg, reduced to 2 mg/kg thereafter for toxicity; 3×4, Three treatments-every fourth day; IV, Intravenously; PO, Oral; IP, Intraperitoneally.

^3.P, Pooled data from multiple experiments as published.

^4.Data published as means indicated by *

^5.Tested on a HER2 transfectant of 231-BR.